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The purpose of this study was to assess the tissue-penetrating ability of a new p-lactam antibiotic,
meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-
mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest
at —1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median
plasma concentration at —1 hour was 13.3 Ag/mL. The median fluid and tissue concentrations at
—1 hour were as follows: cervix, 8.5 µg/g; endometrium, 2.3 µg/g; fallopian tube, 1.9 ig/g; myome-
trium, 3.6 µg/g; ovary, 2.3 µg/g; and uterus, 2.3 µg/g. These tissue concentrations exceed the MICs
of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem
readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations
for treatment of gynecologic infections caused by susceptible pathogens.
The development of new antibiotics is crucial to assure con-
tinued efficacy against common pathogens. In a recent com-
mentary, Levy [1] reminded us that many organisms have de-
veloped resistance to multiple antibiotics in both community
and hospital settings. Furthermore, antibiotics that continue to
be effective often have undesirable side effects that can limit
their usefulness.
Meropenem is a new 0-lactam antibiotic and a member of
the carbapenem class. Meropenem has been shown to be four
times more stable against inactivation by the human renal en-
zyme dehydropeptidase-I [2] than imipenem; therefore, plasma
concentrations of meropenem are adequate without the addition
of an enzyme inhibitor such as cilastatin [3]. The in vitro
activity of meropenem against aerobic and anaerobic organisms
(including /3-lactamase-producing Neisseria gonorrhoeae
[MIC for 90% of strains (MIC 90 ) = 0.12 ktg/mL]), Enterobac-
teriaceae species (MIC 90
 = 0.125 µg/mL), and many non-
fermentative gram-negative rods has been demonstrated to be
superior than those of imipenem and other f3-lactam agents
[4, 5]. The purpose of the current study was to evaluate the
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meropenem concentrations obtainable in gynecologic tissue,
peritoneal fluid, and plasma after administration of a single
intravenous 500-mg dose.
Methods
This multicenter, open-label trial evaluated hospitalized pre-
or perimenopausal women who were older than 18 years of
age, were not breast-feeding, weighed between 44 and 89 kg,
and were scheduled to undergo elective gynecologic surgery.
The Institutional Review Board at each center approved the
study, and all patients gave written informed consent before
enrollment. Meropenem, 500 mg per vial, was supplied by
Zeneca Pharmaceuticals (Wilmington, DE). The contents of
one vial were reconstituted with 10 mL of sterile water for
injection and were further diluted to 100 mL with normal sa-
line; meropenem was administered by intravenous infusion
over 30 minutes within 1 hour of reconstitution, before the
start of surgery.
Biological samples (tissue and peritoneal fluid) were ob-
tained at one of the following four intervals after the start of
meropenem infusion: —1 hour (30 minutes to 1 hour and 30
minutes), —2 hours (1 hour and 31 minutes to 3 hours), —4
hours (3 hours and 1 minute to 5 hours), or —6 hours (5 hours
and 1 minute or longer). The type of biological sample varied
with the type of surgical procedure performed. Plasma samples
were obtained before the administration of meropenem, at the
time that the first tissue or fluid sample was obtained, and
frequently again after the last tissue or fluid sample was ob-
tained. Biological and plasma samples were stored at —70°C
to —80°C until they were analyzed.
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Table 1. Meropenem concentrations in plasma and tissue samples from women undergoing gynecologic surgery.
Sample type
Time after dose (h:min)
0:30-1:30 1:31-3:00 3:01-5:00 ...--5:01
Plasma
Median concentration in pg/mL (range) 13.3 (4.7-33.4) 4.5 (2.0-11.7) 0.8 (0.4-2.2) 0.6 (0.4-6.31)
No. of samples 31 27 13 8
Tissue
Cervix
Median concentration in pg/g (range) 8.5 (5.4-8.5) 3.4 NS NS
No. of samples 2 1
Endometrium
Median concentration in pg/g (range) 2.3 (1.7-10.2) 1.4 (1.0-3.3) NS NS
No. of samples 7 5
Fallopian tube
Median concentration in pg/g (range) 1.9 (0.3-3.4) 0.8 (0.4-2.3) 3.5 0.5 (0.4-0.7)
No. of samples 9 5 1 2
Myometrium
Median concentration in pg/g (range) 3.6 (0.4-8.1) 1.5 (0.5-2.1) 0.4 NS
No. of samples 15 9 1
Ovary
Median concentration in ktg/g (range) 2.3 (0.8-4.8) 1.8 (0.6-5.0) 0.8 (0.3-1.7) NS
No. of samples 8 6 4
Uterus
Median concentration in ,u,g/g (range) 2.3 (1.6-5.1) 1.3 (1.2-1.9) NS NS
No. of samples 3 4
NOTE.	 NS = no samples available.
Routine prophylactic antibiotics were not given until after
all samples were obtained. Validated bioassay procedures were
used to determine the meropenem concentrations in both
plasma (detection limit, 0.25 ii,g/mL) and tissue samples (detec-
tion limit, -1 //gig). All data were summarized with use of the
SAS system (SAS Institute, Cary, NC) and the RS 1 software
package (BBN Software Products Corporation, Cambridge,
MA).
Table 2. In vitro activity of meropenem against gynecologic
pathogens.
Organism
MIC50
(pg/mL)
MIC90
(ktg/mL)
Neisseria gonorrhoeae
/3-Lactamase-negative 0.015 0.03
f3-Lactamase-positive 0.015 0.50
Penicillin-resistant and
/3-lactamase-negative 0.03 0.03
Escherichia coli 0.03 0.03
Streptococcus agalactiae 0.06 0.06
Enterococcus faecalis 4 4
Bacteroides fragilis 0.125 0.25
Peptostreptococcus species 0.125 0.25
NOTE. Table adapted from [6]. MIC 50 = MIC for 50% of strains; MIC90
= MIC for 90% of strains.
Results
Sixty-four patients (mean age ± SD, 38.4 ± 8.1 years; mean
weight ± SD, 71.2 ± 13.9 kg; racial groups: black, 21 patients;
white, 31; Oriental, 11; and other, 1) from four centers were
enrolled in the trial. The pharmacokinetic data for five patients
were excluded; one patient was withdrawn from the study be-
cause of chest pain before receiving meropenem, and four pa-
tients were withdrawn because of cancellation of surgery or
incorrect sampling procedures.
Meropenem showed good penetration into a variety of gyne-
cologic tissues (table 1). The median tissue concentrations aver-
aged -4 Ag/g during the first interval (-1 hour) and decreased
with increasing time. The median peak tissue concentrations
in individual specimens at -1 hour were 14.8% to 52.6% of
the median plasma concentration at -1 hour. At 30 minutes
to 1 hour and 30 minutes, the ratio of the median individual
tissue concentrations to the plasma concentration ranged from
1% to 64%; at 1 hour and 31 minutes to 3 hours, the ratio
ranged from 18% to 76%.
The single sample of peritoneal fluid tested was obtained at
-1 hour; it contained 8.8 kig of meropenem/mL. Collection
times for plasma and tissue samples after the start of infusion
ranged from 5 minutes to -7.5 hours and 45 minutes to -7.25
hours, respectively. Samples taken before 30 minutes were not
used in calculations of medians.
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Nineteen patients (32%) had a total of 33 adverse events;
none were considered by the investigators to be related to
administration of meropenem. The most frequently reported
adverse events (-4 reports) were nausea (7) and pruritus (4).
Discussion
The current study demonstrates that meropenem is safe
and well tolerated. A single 500-mg dose of meropenem
provides adequate tissue concentrations in patients undergo-
ing gynecologic surgery. The median peak tissue concentra-
tions of meropenem at —1 hour were 14.8% to 52.6% of
the median plasma concentration at —1 hour. The tissue
concentrations were well above the MIC 90 values for patho-
gens likely to be associated with gynecologic infections (ta-
ble 2) [6]. The efficacy of meropenem as treatment for pa-
tients with gynecologic infections caused by susceptible
organisms merits further evaluation.
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